Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The "immune system stimulation via AS03 adjuvant pathway" refers not to a single molecular target but rather a coordinated cascade involving local activation/reprogramming of innate immune cells, enhanced recruitment/activation/migration/presentation by APCs, and amplified differentiation/expansion/maturation within adaptive compartments—especially memory B cells producing broadly neutralizing antibodies. This pathway results in superior vaccine efficacy through both quantitative (higher titers) and qualitative (broader specificity, greater avidity) improvements in protective immunity compared with non-adjuvanted formulations.
AS03 activates local innate immune responses, enhances antigen uptake and presentation by APCs, and amplifies adaptive immunity, leading to increased antibody titers, broader cross-protection, and durable immunity.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immune System Stimulation via AS03 Adjuvant Pathway (AS03 Pathway).